Skip to content
ES
MARKETS / NASDAQ / TGTX
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

TG Therapeutics, Inc. TGTX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$616.3M
▲ 87.3% YoY
$447.2M
▲ 1812.4% YoY
$-25.0M
In brief

What this company does

BRIUMVI was first made available in the European market by Neuraxpharm in Germany in February 2024 and is now commercially available in several other countries outside of the U.S. As of February 20, 2026, it had 399 employees. TG Therapeutics was incorporated in Delaware in 1993, and its executive offices are located in Morrisville, North Carolina.

Written from the business description in TG THERAPEUTICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 616.3M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 616.3 · Net income 447.2
250.0M500.0M-200.0M20112013201520172019202120232025
Compound annual growth
+504.9%
+426.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +426.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
73 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 20.0% · Net 72.6%
-50000%-100000%-150000%20112013201520172019202120232025
ROE
FY2025 · ROE 102.8%
50%100%-50%-100%-150%20112013201520172019202120232025
Gross margin83.7%
Operating margin20.0%
Net margin72.6%
Return on assets54.5%
EBITDAUSD 123.4M

Each USD of equity produced 103 cents of profit this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -25.0
-100M-200M20112013201520172019202120232025
Net buybacks $ Dividends $
FY2015 · Dividends — · Net buybacks 0.0
50000100000-80000-1600002012201320142015
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 1.1B
EquityUSD 648.0M
CashUSD 79.1M
Gross debtUSD 245.6M
Net debtUSD 166.5M
Current ratio4.10×

Net debt stands at 26% of equity.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.60.30.20.00.00.00.00.00.00.0·····
Operating income $B0.10.00.0−0.2−0.3−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B0.10.00.0−0.2−0.3−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B−0.30.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.40.00.0−0.2−0.3−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.2−0.3−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EPS, diluted $2.770.150.09−1.65−2.63−2.42−1.96−2.30−1.91−1.60−1.38−1.64−0.81−1.38−0.44
Dividend / sh $···············
Payout %···············
ROE %102.812.211.6−151.4−92.0·······−131.7−143.6−8.9
Shares out B0.160.160.150.150.140.140.110.080.070.060.050.040.030.030.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 60 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 30 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image